These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Vascular endothelial growth factor and retinal neovascularisation: a new therapeutic approach for diabetic retinopathy. Favard C; Ortega N; Bayard F; Plouet J Diabetes Metab; 1996 Jul; 22(4):268-73. PubMed ID: 8767174 [TBL] [Abstract][Full Text] [Related]
6. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Smith LE; Shen W; Perruzzi C; Soker S; Kinose F; Xu X; Robinson G; Driver S; Bischoff J; Zhang B; Schaeffer JM; Senger DR Nat Med; 1999 Dec; 5(12):1390-5. PubMed ID: 10581081 [TBL] [Abstract][Full Text] [Related]
7. [Diabetic retinopathy--the mechanisms of the ocular neovascularization and the development of anti-angiogenic drugs]. Kuroki M; Kawakami M Nihon Rinsho; 1999 Mar; 57(3):584-9. PubMed ID: 10199138 [TBL] [Abstract][Full Text] [Related]
8. Plasma VEGF and soluble VEGF receptor FLT-1 in proliferative retinopathy: relationship to endothelial dysfunction and laser treatment. Lip PL; Belgore F; Blann AD; Hope-Ross MW; Gibson JM; Lip GY Invest Ophthalmol Vis Sci; 2000 Jul; 41(8):2115-9. PubMed ID: 10892852 [TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and diabetic retinopathy: pathophysiological mechanisms and treatment perspectives. Caldwell RB; Bartoli M; Behzadian MA; El-Remessy AE; Al-Shabrawey M; Platt DH; Caldwell RW Diabetes Metab Res Rev; 2003; 19(6):442-55. PubMed ID: 14648803 [TBL] [Abstract][Full Text] [Related]
11. Angiotensin converting enzyme inhibiting therapy is associated with lower vitreous vascular endothelial growth factor concentrations in patients with proliferative diabetic retinopathy. Hogeboom van Buggenum IM; Polak BC; Reichert-Thoen JW; de Vries-Knoppert WA; van Hinsbergh VW; Tangelder GJ Diabetologia; 2002 Feb; 45(2):203-9. PubMed ID: 11935151 [TBL] [Abstract][Full Text] [Related]
12. [Growth factors binding heparin: FGF and VEGF. Physiological and physiopathological importance, therapeutic implications in diabetic retinopathy]. Favard C; Patry V; Prats H; Plouet J; Bayard F Journ Annu Diabetol Hotel Dieu; 1995; ():39-51. PubMed ID: 7602891 [No Abstract] [Full Text] [Related]
13. The interaction between the renin-angiotensin system and vascular endothelial growth factor in the pathogenesis of retinal neovascularization in diabetes. Wilkinson-Berka JL; Kelly DJ; Gilbert RE J Vasc Res; 2001; 38(6):527-35. PubMed ID: 11740151 [TBL] [Abstract][Full Text] [Related]
14. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Flyvbjerg A Diabetologia; 2000 Oct; 43(10):1205-23. PubMed ID: 11079738 [TBL] [Abstract][Full Text] [Related]
15. Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. Amin RH; Frank RN; Kennedy A; Eliott D; Puklin JE; Abrams GW Invest Ophthalmol Vis Sci; 1997 Jan; 38(1):36-47. PubMed ID: 9008628 [TBL] [Abstract][Full Text] [Related]
18. [Molecular mechanisms of vasculogenesis and angiogenesis. What regulates vascular growth?]. Joussen AM; Kirchhof B; Gottstein C Ophthalmologe; 2003 Apr; 100(4):284-91. PubMed ID: 12682760 [TBL] [Abstract][Full Text] [Related]
19. Molecular mechanisms of retinal neovascularization in diabetic retinopathy. Takagi H Intern Med; 2003 Mar; 42(3):299-301. PubMed ID: 12705804 [No Abstract] [Full Text] [Related]
20. A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Barber AJ Prog Neuropsychopharmacol Biol Psychiatry; 2003 Apr; 27(2):283-90. PubMed ID: 12657367 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]